Department of Haematology, Hull & East Yorkshire Hospitals NHS Trust, Hull, East Yorkshire, England, UK.
Future Oncol. 2017 Dec;13(29):2611-2628. doi: 10.2217/fon-2017-0275. Epub 2017 Aug 29.
Ofatumumab has been extensively studied in the treatment of B-cell malignancies. Currently, it has been approved for the treatment of chronic lymphocytic leukemia in a number of different situations. However, there is still no compelling evidence confirming the superiority of ofatumumab over rituximab in vivo. In this article, we summarize the currently available clinical data supporting the use of ofatumumab in the treatment of B-cell malignancies. The clinical studies were searched from clinicaltrials.gov with the key words ofatumumab, HuMax-CD20. Out of 115 trials available, studies for B-cell malignancies were selected, followed by selection of completed studies with results and active ongoing studies. The results from completed studies were thoroughly analyzed and active ongoing studies were listed in tables.
奥法妥珠单抗在治疗 B 细胞恶性肿瘤方面已经进行了广泛的研究。目前，它已被批准用于多种不同情况下的慢性淋巴细胞白血病的治疗。然而，目前仍没有确凿的证据证实奥法妥珠单抗在体内优于利妥昔单抗。在本文中，我们总结了目前支持奥法妥珠单抗用于治疗 B 细胞恶性肿瘤的临床数据。通过在 clinicaltrials.gov 上以奥法妥珠单抗、HuMax-CD20 为关键词进行检索，获取了 115 项临床试验，从中筛选出了针对 B 细胞恶性肿瘤的研究，然后选择了已完成且有结果的研究和正在进行的研究。对已完成研究的结果进行了详细分析，并列出了正在进行的研究。
